犬用疫苗市场－全球产业规模、份额、趋势、机会及预测（按类型、疾病类型、给药途径、成分、地区和竞争格局划分，2021-2031年）

全球犬用疫苗市场预计将从2025年的30.6亿美元成长到2031年的45.7亿美元，复合年增长率（CAGR）为6.92%。这些生物製药对于诱导犬隻对特定病原体产生主动免疫至关重要，能够有效保护犬隻免受狂犬病、犬细小病毒和犬瘟热等严重的侵害。市场成长的主要驱动力是通用感染疾病发病率的上升以及宠物饲主日益重视预防性兽医护理。宠物人性化趋势的兴起进一步推动了这一成长势头，饲主更加重视高品质的医疗保健。根据英国宠物食品协会的数据，英国犬隻数量预计将在2024年达到1,350万隻，这将显着推动对动物健康和公共卫生所需疫苗产品的需求。

儘管有这些驱动因素，低温运输仓储物流的复杂性仍构成市场发展的重大障碍。运输和配送过程中严格的温度控制要求增加了营运成本，并限制了基础设施薄弱地区的产品供应，从而阻碍了市场的进一步扩张。确保整个供应链中精确的温度条件的严格要求会增加成本并降低可及性，这对该行业的全球扩张构成重大挑战。

市场驱动因素

动物医疗保健成本的不断上涨以及宠物人性化趋势的日益加深是推动市场成长的关键因素。饲主越来越将狗视为家庭成员，并认为它们理应享有与人类同等的医疗保健标准，这显着扩大了对高品质疫苗产品的需求。产业数据也印证了这一投资观点。根据美国宠物产品协会发布的《2025年产业趋势报告》，预计到2024年，美国宠物产业的总支出将达到创纪录的1,520亿美元。这笔巨额资金的流入确保了兽医服务和先进疫苗接种通讯协定的持续资金支持。硕腾公司（Zoetis）的业绩也印证了这个趋势。该公司公布的2025年第三季营收为24亿美元，主要得益于其伴侣动物产品组合的成长。

此外，通用和犬类感染疾病的日益普及感染疾病亟需严格执行疫苗接种规定和快速反应措施的关键因素。狂犬病等持续存在的威胁不断给公共卫生系统带来压力，促使各国政府实施严格的疫苗接种计划，以维持群体免疫并防止跨物种传播。美国动物医院协会 (AAHA) 于 2025 年 9 月发布的流行病学数据显示，目前美国20 个州正在追踪 14 起疑似狂犬病疫情，凸显了这一问题的迫切性。疫情的再次爆发促使人们迅速部署预防方案，并强调了疫苗在保护动物福利和人类安全方面发挥的关键作用。

市场挑战

低温运输仓储的物流复杂性是全球犬用疫苗市场扩张的一大障碍。犬用疫苗属于生物製药，需要从生产设施到给药点全程严格且不间断地进行温度控制。在基础设施薄弱或电力供应不稳定的地区，这种温度稳定性无法得到保证，加剧产品劣化和效力损失。这种不稳定性迫使生产商不得不投入成本购买昂贵的替代品和专用运输设备，显着增加营运成本，并使分销物流更加复杂。

因此，高成本直接阻碍了市场成长，因为对许多宠物主人来说，疫苗接种费用难以负担。高成本和分销困难导致疫苗接种率低下，从而有效地抑制了市场规模。例如，HealthforAnimals发布的《2024年全球趋势报告》发现，英国约有25%的宠物饲主尚未为他们的狗接种疫苗。这个潜在市场的巨大缺口表明，严格的物流要求造成的准入障碍和成本影响如何有效地阻碍了市场渗透和获利能力。

市场趋势

随着重组DNA和mRNA疫苗技术的应用，市场正经历着一场根本性的变革时期，从传统的生产方式转向合成和精准的平台。这种变革使製造商能够快速开发针对不断演变的病毒株的疫苗，提高安全性并消除通常会引起局部反应的佐剂。 2024年6月，默克动物保健公司（Merck Animal Health）的Novivac® NXT犬流感H3N2疫苗获得商业性核准，这是首个基于RNA颗粒技术的犬流感疫苗，证明了这一趋势的商业可行性。与传统技术相比，这项创新技术简化了生产流程，并能更快地应对新出现的病原体变种。

同时，犬类肿瘤治疗性疫苗的出现正将该领域从单纯的预防转向积极的疾病管理。这些免疫疗法旨在重新训练犬隻的免疫系统，使其攻击现有的癌细胞，为常见癌症提供了一种非侵入性的化疗替代方案。这些疫苗的治疗潜力得到了显着的临床进展的支持。根据耶鲁大学新闻2024年3月的一篇报导，新型免疫疗法疫苗已将患有某些癌症的犬隻的12个月存活率从约35%提高到60%。这些治疗方法进展正在开闢一个盈利的市场领域，专门针对老年犬的慢性疾病管理。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球犬用疫苗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（减毒活病毒疫苗、不活化疫苗、其他）
  • 依疾病类型分类（犬瘟热、犬传染性呼吸道疾病症候群 (CIRDC)、犬小病毒/细小病毒病、犬钩端螺旋体病、犬莱姆病、犬传染性肝炎、犬狂犬病、其他疾病）
  • 给药途径（注射、鼻腔、口服）
  • 按成分（联合疫苗、单一疫苗）
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美犬用疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球犬用疫苗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc.
• Bioveta as
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac SA
• Zendal Group
• Elanco Animal Health Incorporated

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Dog Vaccine Market is projected to expand from a valuation of USD 3.06 billion in 2025 to USD 4.57 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.92%. These biological formulations are essential for generating active immunity against specific pathogens, effectively shielding canines from severe conditions such as rabies, parvovirus, and distemper. The market's growth is primarily driven by the increasing incidence of zoonotic diseases and a widening base of pet owners dedicated to preventive veterinary medicine. This momentum is further strengthened by the trend of pet humanization, where owners prioritize high-quality healthcare. Data from UK Pet Food indicates that the dog population in the United Kingdom hit 13.5 million in 2024, a density that significantly boosts the demand for immunization products required for animal health and public safety.

Despite these favorable drivers, the market faces substantial hurdles related to the logistical intricacies of cold chain storage. The necessity of maintaining strict temperature controls during transport and distribution drives up operational costs and restricts product availability in regions with inadequate infrastructure, thereby limiting broader market expansion. The rigorous requirement to ensure precise thermal conditions throughout the supply chain can inflate expenses and impede accessibility, posing a significant challenge to the industry's global reach.

Market Driver

The escalating expenditure on animal healthcare and the deepening trend of pet humanization act as the primary catalysts for market growth. Owners increasingly view dogs as integral family members deserving of healthcare standards comparable to humans, a perspective that significantly amplifies the demand for premium vaccine formulations. This readiness to invest is corroborated by industry data; the American Pet Products Association's "2025 State of the Industry Report" noted that total U.S. pet industry spending reached a record $152 billion in 2024. Such substantial financial injection ensures continuous funding for veterinary services and advanced immunization protocols, a trend further validated by Zoetis, which reported $2.4 billion in revenue for the third quarter of 2025 largely due to its companion animal portfolio's performance.

Additionally, the rising prevalence of zoonotic and canine infectious diseases is a critical driver necessitating strict vaccination mandates and rapid response initiatives. persistent threats like rabies continue to pressure public health systems, compelling governments to enforce rigorous immunization schedules to maintain herd immunity and prevent cross-species transmission. The urgency of this matter is highlighted by recent epidemiological data from the American Animal Hospital Association's September 2025 report, which is currently tracking 14 potential rabies outbreaks across 20 U.S. states. This resurgence accelerates the mobilization of prophylaxis programs and underscores the essential role vaccines play in safeguarding both animal welfare and human safety.

Market Challenge

The logistical complexities of cold chain storage represent a formidable barrier to the expansion of the Global Dog Vaccine Market. Canine vaccines are biologically sensitive products that demand strict, uninterrupted temperature maintenance from the manufacturing facility to the point of administration. In areas with poor infrastructure or unreliable power grids, the inability to guarantee this thermal stability results in significant product spoilage and loss of efficacy. This volatility forces manufacturers to incur costs for expensive replacements and specialized transport equipment, which drastically inflates operational expenses and complicates distribution logistics.

Consequently, these elevated costs directly impede market growth by rendering immunization economically unviable for a large segment of the pet-owning population. The high expense and difficulty of distribution result in lower immunization coverage, effectively capping the market's transaction volume. For instance, a 2024 global trends report by HealthforAnimals revealed that approximately 25% of pet owners in the United Kingdom had not provided a primary course of vaccinations for their dogs. This significant gap in the addressable market illustrates how access barriers and cost implications, driven by rigid logistical requirements, effectively stall market penetration and revenue potential.

Market Trends

The market is undergoing a fundamental shift with the adoption of recombinant DNA and mRNA vaccine technologies, moving away from conventional production methods toward synthetic, high-precision platforms. This evolution enables manufacturers to rapidly develop immunizations for mutating viral strains with enhanced safety, eliminating adjuvants that often cause local reactions. The commercial viability of this trend was confirmed in June 2024, when Merck Animal Health received approval for the first canine influenza vaccine built on RNA-particle technology, known as NOBIVAC(R) NXT Canine Flu H3N2. This innovation streamlines manufacturing processes and allows for a faster response to emerging pathogen variants compared to traditional techniques.

Simultaneously, the emergence of therapeutic vaccines for canine oncology is transforming the sector from a purely preventive landscape into one focused on active disease management. These immunotherapies are designed to retrain the canine immune system to attack existing tumor cells, offering a non-invasive alternative to chemotherapy for high-prevalence cancers. The therapeutic potential of these vaccines is supported by significant clinical progress; a March 2024 article by YaleNews reported that a new immunotherapy vaccine increased 12-month survival rates for dogs with certain cancers from approximately 35% to 60%. As these treatments advance, they open a lucrative market segment targeting chronic disease management in aging dogs.

Key Market Players

• Zoetis Inc.
• Bioveta a.s
• Hester Biosciences Limited
• Boehringer Ingelheim International GmbH
• Brilliant Bio Pharma Private Limited
• Heska Corporation
• Merck & Co., Inc.
• Virbac S.A.
• Zendal Group
• Elanco Animal Health Incorporated

Report Scope

In this report, the Global Dog Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dog Vaccine Market, By Type

• Modified/ Attenuated Live
• Inactivated (Killed)
• Others

Dog Vaccine Market, By Disease Type

• Canine Distemper
• Canine Infectious Respiratory Disease Complex (CIRDC)
• Canine Parvoviruses/ Parvovirus Disease
• Canine Leptospirosis
• Canine Lyme Disease
• Infectious Canine Hepatitis
• Canine Rabies
• Other Diseases

Dog Vaccine Market, By Route of Administration

• Injectable
• Intranasal
• Oral

Dog Vaccine Market, By Component

• Combined Vaccines
• Mono Vaccines

Dog Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dog Vaccine Market.

Available Customizations:

Global Dog Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Dog Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Modified/ Attenuated Live, Inactivated (Killed), Others)
  • 5.2.2. By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex (CIRDC), Canine Parvoviruses/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Other Diseases)
  • 5.2.3. By Route of Administration (Injectable, Intranasal, Oral)
  • 5.2.4. By Component (Combined Vaccines, Mono Vaccines)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Dog Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Component
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Dog Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Component
  • 6.3.2. Canada Dog Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Component
  • 6.3.3. Mexico Dog Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Component

7. Europe Dog Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Component
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Dog Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Component
  • 7.3.2. France Dog Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Component
  • 7.3.3. United Kingdom Dog Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Component
  • 7.3.4. Italy Dog Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Component
  • 7.3.5. Spain Dog Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Component

8. Asia Pacific Dog Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Component
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Dog Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Component
  • 8.3.2. India Dog Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Component
  • 8.3.3. Japan Dog Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Component
  • 8.3.4. South Korea Dog Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Component
  • 8.3.5. Australia Dog Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Component

9. Middle East & Africa Dog Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Component
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Dog Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Component
  • 9.3.2. UAE Dog Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Component
  • 9.3.3. South Africa Dog Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Component

10. South America Dog Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Component
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Dog Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Component
  • 10.3.2. Colombia Dog Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Component
  • 10.3.3. Argentina Dog Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Component

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Dog Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Bioveta a.s
• 15.3. Hester Biosciences Limited
• 15.4. Boehringer Ingelheim International GmbH
• 15.5. Brilliant Bio Pharma Private Limited
• 15.6. Heska Corporation
• 15.7. Merck & Co., Inc.
• 15.8. Virbac S.A.
• 15.9. Zendal Group
• 15.10. Elanco Animal Health Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer